Cargando…
Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes
BACKGROUND: Previous studies have been conducted to assess pneumothorax. However, few studies were done to assess pneumothorax in COVID-19 patients in the intensive care unit (ICU). OBJECTIVE: Our aim is to describe and analyze the prevalence, clinical characteristics, risk factors, and outcomes of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698325/ https://www.ncbi.nlm.nih.gov/pubmed/36438021 http://dx.doi.org/10.2147/IJGM.S387868 |
_version_ | 1784838787697737728 |
---|---|
author | AlGhamdi, Zeead Alqahtani, Shaya Y AlDajani, Khalid Alsaedi, Ammar Al-Rubaish, Omar Alharbi, Abdulmajeed Elbawab, Hatem |
author_facet | AlGhamdi, Zeead Alqahtani, Shaya Y AlDajani, Khalid Alsaedi, Ammar Al-Rubaish, Omar Alharbi, Abdulmajeed Elbawab, Hatem |
author_sort | AlGhamdi, Zeead |
collection | PubMed |
description | BACKGROUND: Previous studies have been conducted to assess pneumothorax. However, few studies were done to assess pneumothorax in COVID-19 patients in the intensive care unit (ICU). OBJECTIVE: Our aim is to describe and analyze the prevalence, clinical characteristics, risk factors, and outcomes of COVID-19 pneumothorax patients in the intensive care unit. METHODS: We performed a retrospective review of the medical records of 418 patients, who tested positive for COVID-19 by polymerase chain reaction test and required ICU admission in King Fahad Hospital of The University from 02/01/2020 to 01/09/2021. A total number of 36 pneumothorax patients were included in the study. RESULTS: Of 418 patients who were followed up in the intensive care unit as COVID-19 cases, 36 patients developed a pneumothorax (8.61%). The mean age of the patients was 55.6 ± 15.06 years, 23 patients were male, and 13 were female. Seventeen patients were obese, and only one patient was an active smoker. Twenty-four patients had at least one comorbidity; hypertension was the most common. Thirty-two patients were intubated, and the duration of intubation was 23.23 ±15.9 days. The time from intubation to pneumothorax development was 8.8 ± 9.3 days. Six patients were on bilevel positive airway pressure ventilation (BIPAP), 2 patients on continuous positive airway pressure ventilation (CPAP), 3 patients on High-Flow Nasal Cannula ventilation (HFNC), 9 patients on pressure-control ventilation (PC), and 16 patients on pressure regulated volume control ventilation (PRVC). Of 36 patients, 26 died, and the mortality rate was 72.2%. CONCLUSION: Our study showed that risk factors of pneumothorax occurrence in COVID-19 critically ill patients include male patients, hypertension, diabetes mellitus, endotracheal intubation and mechanical ventilation. More efforts should be made to determine the risk factors and assess the outcomes of those patients to develop preventive measures and management guidelines. |
format | Online Article Text |
id | pubmed-9698325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96983252022-11-26 Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes AlGhamdi, Zeead Alqahtani, Shaya Y AlDajani, Khalid Alsaedi, Ammar Al-Rubaish, Omar Alharbi, Abdulmajeed Elbawab, Hatem Int J Gen Med Original Research BACKGROUND: Previous studies have been conducted to assess pneumothorax. However, few studies were done to assess pneumothorax in COVID-19 patients in the intensive care unit (ICU). OBJECTIVE: Our aim is to describe and analyze the prevalence, clinical characteristics, risk factors, and outcomes of COVID-19 pneumothorax patients in the intensive care unit. METHODS: We performed a retrospective review of the medical records of 418 patients, who tested positive for COVID-19 by polymerase chain reaction test and required ICU admission in King Fahad Hospital of The University from 02/01/2020 to 01/09/2021. A total number of 36 pneumothorax patients were included in the study. RESULTS: Of 418 patients who were followed up in the intensive care unit as COVID-19 cases, 36 patients developed a pneumothorax (8.61%). The mean age of the patients was 55.6 ± 15.06 years, 23 patients were male, and 13 were female. Seventeen patients were obese, and only one patient was an active smoker. Twenty-four patients had at least one comorbidity; hypertension was the most common. Thirty-two patients were intubated, and the duration of intubation was 23.23 ±15.9 days. The time from intubation to pneumothorax development was 8.8 ± 9.3 days. Six patients were on bilevel positive airway pressure ventilation (BIPAP), 2 patients on continuous positive airway pressure ventilation (CPAP), 3 patients on High-Flow Nasal Cannula ventilation (HFNC), 9 patients on pressure-control ventilation (PC), and 16 patients on pressure regulated volume control ventilation (PRVC). Of 36 patients, 26 died, and the mortality rate was 72.2%. CONCLUSION: Our study showed that risk factors of pneumothorax occurrence in COVID-19 critically ill patients include male patients, hypertension, diabetes mellitus, endotracheal intubation and mechanical ventilation. More efforts should be made to determine the risk factors and assess the outcomes of those patients to develop preventive measures and management guidelines. Dove 2022-11-21 /pmc/articles/PMC9698325/ /pubmed/36438021 http://dx.doi.org/10.2147/IJGM.S387868 Text en © 2022 AlGhamdi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research AlGhamdi, Zeead Alqahtani, Shaya Y AlDajani, Khalid Alsaedi, Ammar Al-Rubaish, Omar Alharbi, Abdulmajeed Elbawab, Hatem Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title | Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title_full | Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title_fullStr | Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title_full_unstemmed | Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title_short | Pneumothorax in Critically Ill COVID-19 Patients: Prevalence, Analysis of Risk Factors and Clinical Outcomes |
title_sort | pneumothorax in critically ill covid-19 patients: prevalence, analysis of risk factors and clinical outcomes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698325/ https://www.ncbi.nlm.nih.gov/pubmed/36438021 http://dx.doi.org/10.2147/IJGM.S387868 |
work_keys_str_mv | AT alghamdizeead pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT alqahtanishayay pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT aldajanikhalid pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT alsaediammar pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT alrubaishomar pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT alharbiabdulmajeed pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes AT elbawabhatem pneumothoraxincriticallyillcovid19patientsprevalenceanalysisofriskfactorsandclinicaloutcomes |